Literature DB >> 19324992

Identification of cystic fibrosis variants by polymerase chain reaction/oligonucleotide ligation assay.

Karen M Schwartz1, Lisa L Pike-Buchanan, Kasinathan Muralidharan, Joy B Redman, Jean Amos Wilson, Michael Jarvis, M Grace Cura, Victoria M Pratt.   

Abstract

The purpose of this work is to define rare variants of cystic fibrosis (CF) that are potential sources of error and can confound molecular genetic testing methods. We performed routine, clinical CF mutation screening using a laboratory-developed test and the oligonucleotide ligation assay reagents from Abbott/Celera. In this report, we describe 11 unique allele drop outs [3849 + 10kb C>T (NM_000492.2:c.3718-2477C>T), V520F (c.1558G>T), 1078delT (c.948delT), A455E (c.1364C>A), R347P (c.1040G>C), 2184delA (c.2052delA), W1282X (c.3846G>A), R117H (c.350G>A), G85E (c.254G>A), 621 + 1G>T (c.489 + 1G>T), and 2789 + 5G>A (c.2657 + 5G>A)] observed with this platform. The allele drop outs account for less than 0.01% of all results reported in our laboratory. Both the recognition and enumeration of such variants along with clinical information in CF testing is valuable in avoiding false-positive and false-negative results.

Entities:  

Mesh:

Year:  2009        PMID: 19324992      PMCID: PMC2671338          DOI: 10.2353/jmoldx.2009.080106

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  8 in total

1.  ACOG Committee Opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis.

Authors: 
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

2.  Indirect CFTR mutation identification by PCR/OLA anomalous electropherograms.

Authors:  Pietro Stanziale; Maria Savino; Patrizia De Bonis; Matteo Granatiero; Leopoldo Zelante; Luigi Bisceglia
Journal:  Genet Test       Date:  2005

3.  Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen.

Authors:  Denise LaMarche Heaney; Patrick Flume; Lauren Hamilton; Elaine Lyon; Daynna J Wolff
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Introduction to PCR/OLA/SCS, a multiplex DNA test, and its application to cystic fibrosis.

Authors:  E C Brinson; T Adriano; W Bloch; C L Brown; C C Chang; J Chen; F A Eggerding; P D Grossman; D M Iovannisci; A M Madonik; D G Sherman; R W Tam; E S Winn-Deen; S L Woo; S Fung; D A Iovannisci
Journal:  Genet Test       Date:  1997

5.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

6.  Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples.

Authors:  Charles M Strom; Donghui Huang; Arlene Buller; Joy Redman; Beryl Crossley; Ben Anderson; Tom Entwistle; Weimin Sun
Journal:  Genet Med       Date:  2002 Jul-Aug       Impact factor: 8.822

7.  Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test.

Authors:  Charles M Strom; Donghui Huang; Christina Chen; Arlene Buller; Mei Peng; Franklin Quan; Joy Redman; Weimin Sun
Journal:  Genet Med       Date:  2003 Jan-Feb       Impact factor: 8.822

8.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.

Authors:  Michael S Watson; Garry R Cutting; Robert J Desnick; Deborah A Driscoll; Katherine Klinger; Michael Mennuti; Glenn E Palomaki; Bradley W Popovich; Victoria M Pratt; Elizabeth M Rohlfs; Charles M Strom; C Sue Richards; David R Witt; Wayne W Grody
Journal:  Genet Med       Date:  2004 Sep-Oct       Impact factor: 8.822

  8 in total
  5 in total

1.  Cystic fibrosis testing comes of age.

Authors:  Wayne W Grody
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

2.  A simple microfluidic assay for the detection of ligation product.

Authors:  Lei Zhang; Jingjing Wang; Johann Roebelen; Anubhav Tripathi
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

3.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

4.  Multidisciplinary approach to patients with manifestations and pulmonary complications of cystic fibrosis.

Authors:  Viorel Biciuşcă; Ileana Octavia Petrescu; Cristina Elena Singer; Anca Gabriela Oancea; Ana Maria Petrescu; Ionelia Sorina Stan; Patricia Durand; Citto Iulian Taisescu; Daniela Dumitrescu; Mihaela Amelia Dobrescu; Ion Udriştoiu; Diana Rodica Tudoraşcu; Florin Petrescu
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

5.  An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations.

Authors:  Zecheng Zhong; Jin Wang; Shuizhen He; Xiaosong Su; Weida Huang; Mengyuan Chen; Zhihao Zhuo; Xiaomei Zhu; Mujin Fang; Tingdong Li; Shiyin Zhang; Shengxiang Ge; Jun Zhang; Ningshao Xia
Journal:  Biosens Bioelectron       Date:  2022-01-31       Impact factor: 10.618

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.